相似文献
1
Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies.
BJOG. 2014 Oct;121 Suppl 5(0 5):53-61. doi: 10.1111/1471-0528.12843.
2
Topical microbicides for prevention of sexually transmitted infections.
Cochrane Database Syst Rev. 2012 Jun 13(6):CD007961. doi: 10.1002/14651858.CD007961.pub2.
3
Topical microbicides--what's new?
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S144-9. doi: 10.1097/QAI.0b013e3182986f80.
4
Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD007189. doi: 10.1002/14651858.CD007189.pub3.
5
Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis.
BMC Infect Dis. 2012 Nov 6;12:289. doi: 10.1186/1471-2334-12-289.
6
Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):124-7. doi: 10.1097/QAI.0b013e31824f53a9.
7
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
Trials. 2011 Mar 7;12:67. doi: 10.1186/1745-6215-12-67.
8
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-human, phase 1 trial.
Lancet HIV. 2025 Aug;12(8):e556-e567. doi: 10.1016/S2352-3018(25)00079-7. Epub 2025 Jun 27.
9
Interest in multipurpose prevention of HIV and pregnancy: perspectives of women, men, health professionals and community stakeholders in two vaginal gel studies in southern Africa.
BJOG. 2014 Oct;121 Suppl 5:45-52. doi: 10.1111/1471-0528.12875.
10
Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial.
AIDS Behav. 2014 May;18(5):849-54. doi: 10.1007/s10461-014-0696-0.
引用本文的文献
1
Understanding women's motivations to participate in MTN-003/VOICE, a phase 2b HIV prevention trial with low adherence.
BMC Womens Health. 2019 Jan 25;19(1):18. doi: 10.1186/s12905-019-0713-6.
2
How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe.
AIDS Behav. 2018 Mar;22(3):877-886. doi: 10.1007/s10461-017-1685-x.
本文引用的文献
1
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges.
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16145-50. doi: 10.1073/pnas.1311355110. Epub 2013 Sep 16.
2
Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence.
Lancet Infect Dis. 2013 Sep;13(9):797-808. doi: 10.1016/S1473-3099(13)70155-5. Epub 2013 Jul 19.
3
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet. 2013 Jun 15;381(9883):2083-90. doi: 10.1016/S0140-6736(13)61127-7. Epub 2013 Jun 13.
4
Feasibility of a breath test for monitoring adherence to vaginal administration of antiretroviral microbicide gels.
J Clin Pharmacol. 2013 Jan;53(1):103-11. doi: 10.1177/0091270011434157. Epub 2013 Jan 24.
5
A novel breath test to directly measure use of vaginal gel and condoms.
AIDS Behav. 2013 Jul;17(6):2211-21. doi: 10.1007/s10461-012-0390-z.
6
Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.
J Infect Dis. 2012 Oct 1;206(7):993-1001. doi: 10.1093/infdis/jis465. Epub 2012 Jul 24.
7
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
N Engl J Med. 2012 Aug 2;367(5):423-34. doi: 10.1056/NEJMoa1110711. Epub 2012 Jul 11.
8
A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use.
AIDS Res Hum Retroviruses. 2012 Nov;28(11):1476-84. doi: 10.1089/aid.2012.0087. Epub 2012 Jul 30.
9
An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
Clin Trials. 2012 Aug;9(4):377-84. doi: 10.1177/1740774512445512. Epub 2012 May 18.
10
Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa.
J Infect Dis. 2012 Jul 1;206(1):6-14. doi: 10.1093/infdis/jis298. Epub 2012 Apr 19.
Zotero 插件